RT Journal Article
SR Electronic
T1 Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.05.21260052
DO 10.1101/2021.07.05.21260052
A1 Aishwarya Iyer
A1 Dylan Hennessey
A1 Robert Gniadecki
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.05.21260052.abstract
AB Background Mature T-cell lymphomas (TCLs) are rare, clinically heterogeneous hematologic cancers of high medical need. TCLs have inferior prognosis compared with their B-cell counterparts, which is attributed to poor understanding of their pathogenesis. Based on phenotypic similarities between normal and neoplastic lymphocytes it has been assumed that TCLs develop in the periphery, directly from various subtypes of normal T-cells.Methods and findings To address the debated question of the cell of origin in TCLs we analyzed to identify the highly variable complementarity determining regions (CDR3) regions of T-cell receptor (TCR) to trace the clonal history of the T-cells. We have collected previously published whole genome-exome, and -transcriptome sequencing data from 574 TCL patients comprising five nodal lymphomas [anaplastic large cell lymphoma (n=67), peripheral T-cell lymphoma (PTCL, n=55), adult T-cell lymphoma/leukemia (n=135), natural killer T-cell lymphoma (NKCL, n=25), not specified/other (n=30)] and three extranodal, cutaneous T-cell lymphomas [mycosis fungoides (n=122), Sezary syndrome (n=130), and subcutaneous panniculitis-like T-cell lymphoma (n=10)]. TCR clonotypes contained in the tumor cell fraction, representing the clonotypes of malignant cells, were identified by de novo assembly of CDR3 regions of TCR γ, β and α. We have found that the vast majority of TCLs are clonotypically oligoclonal, although the pattern oligoclonality varied. Anaplastic large cell lymphoma was most diverse comprising multiple clonotypes of TCRγ, β and α whereas adult T-cell lymphoma/leukemia and peripheral T-cell lymphomas often showed monoclonality for TCRγ and β but had diverse TCRα clonotypes. These patterns of rearrangements were not compatible with the current mature T-cell precursor model and indicated that TCLs are initiated at the level of the lymphoid precursor. In keeping with this hypothesis, TCR rearrangements in TCLs resembled the pattern seen in the human thymus showing biased usage of V and J segments of high combinatorial probability resulting in recurrent, “public” CDR3 sequences shared between unrelated patients and across different clinical TCL entities. Frequencies of malignant clonotypes followed Zipf-Mandelbrot scaling law suggesting that TCLs comprise an interconnected system of expanding tumor clones.The major limitation of this study is that it is based on the analysis of the TCR clonotypes and does not directly inform about developmental trajectories of cellular clones.Conclusions Lymphoid precursors are the likely cells of origin for mature T-cell lymphomas. Anaplastic large cell lymphoma seems to be derived from the most immature precursors with germline TCR whereas peripheral T-cell lymphoma and adult T-cell lymphoma/leukemia map to the later stages after TCRβ rearrangement stage. Clonotypically diverse initiating cells may seed target tissues being responsible for disease relapses after therapy.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare: RG ﹣ no support from any organisation for the submitted work; speaker honoraria and advisory board honoraria from the following organisations that might have an interest in the submitted work - Mallinckrodt, Lilly, Sanofi, Abbvie, Sunpharma, Kyowa Kirin; no other relationships or activities that could appear to have influenced the submitted work. Other authors ﹣ no competing interests.Clinical TrialThe trial though collects human genome data does not administer any treatment that requires a clinical trial registration.Funding StatementThe authors would like to thank the NIH Data access committee and EGA European Genome-Phenome Archive database for their help with getting access to certain restricted datasets. This research was funded by the unrestricted grants from the University of Alberta (Canada) and Bispebjerg Hospital (Copenhagen, Denmark), Danish Cancer Society (R124-A7592 Rp12350), Canadian Dermatology Foundation (CDF) and University Hospital Foundation (University of Alberta). Additionally Dr. Aishwarya Iyer was funded under the accelerate postdoctoral fellowship under a joint grant from the Mitacs and Sun Pharma Global FZE. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:To access the human genome data from restricted databases such as dbGaP and EGA was provided by Health Research Ethics Board of Alberta Cancer Committee under ethics ID- HREBA.CC-20-0118.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data accession number for all studies have been listed in supplementary table 1.